deltatrials

Medical University of Graz Clinical Trials

Sponsors / Medical University of Graz

ClinicalTrials.gov lists 381 trials for which Medical University of Graz is named as lead sponsor. The portfolio currently includes 56 recruiting studies, 9 active non-recruiting studies, and 225 completed studies. 17 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, efficacy or futility findings. Cumulative planned enrollment across all listed trials is 127,772 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.

381
Total Trials
56
Recruiting
9
Other Active
225
Completed
17
Terminated / Withdrawn
127,772
Total Enrollment

Termination reasons: Recruitment53% · Other29% · Efficacy12% · Safety6%

Recent Terminations

  • NCT06302959 Stopped Sep 2025
    Severe Eosinophilic Asthma
    "Recruitment failure"
  • NCT04954573 Phase NA Stopped Feb 2024
    Morphea (Circumscribed Scleroderma)
    "The study was prematurely terminated due to recruitment difficulties."
  • NCT03222102 Phase NA Stopped Nov 2023
    Liver Transplantation
    "Due to the changed standard regarding access for liver transplantation, this no longer complied with the requirements of the study protocol."
  • NCT05142540 Stopped Oct 2022
    Anti-SARS-CoV-2 Antibody Response
    "No more booster vaccinations are being carried out at the site. Further recruitment is therefore not possible."
  • NCT04535908 Phase NA Stopped May 2022
    Prostate Cancer
    "Treatment standard has changed."
  • NCT04657393 Phase NA Stopped Nov 2021
    Apnea
    "slow inclusion"
  • NCT03472833 Phase PHASE3 Stopped Apr 2021
    Pancreas Cancer
    "slow recruitment, patients lost to follow-up due to Covid-19 pandemic."
  • NCT03308435 Stopped Dec 2020
    Aortic Valve Stenosis
    "futility"
  • NCT03559309 Phase PHASE4 Stopped Feb 2020
    Atherosclerosis
    "COVID-19 Pandemic Measures"
  • NCT03509207 Phase PHASE2 Stopped Feb 2019
    Carcinosarcomas Uterine
    "The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe"

Active Trials (9 total)

Top Conditions

Top Locations